Skip to main content

Table 1 Patients 2006–2016 (n = 1535)a

From: Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

Metastatic Melanoma (mM)

623 patients

 62% male, 38% female

 Median age, 53 years,

 Range, 19–84 years

Metastatic Renal Cell Cancer (mRCC)

919 patients

 72% male, 28% female

 Median age, 57 years,

 Range, 18–84 years

7 patients had both mM and mRCC – counted in each subset

Data retrospectively accrued

426 patients

Data prospectively accrued

1109 patients (72%)

Median follow-up

3.5+ years, range 1–8+ years

  1. a7 patients had both diseases